{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:23:53Z","timestamp":1787009033027,"version":"build-2736575974"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Long-acting (LA) intramuscular cabotegravir (CAB) and rilpivirine (RPV) represent a novel antiretroviral therapy (ART) option for people with HIV (PWH), offering improved adherence and patient convenience. The aim was to evaluate plasma and intracellular (IC) exposure of CAB and RPV in PWH switching from oral ART to LA injectable regimens and to assess correlations with virological outcomes and clinical parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a monocentric prospective observational cohort study. We enrolled 177 PWH who switched to CAB\/RPV intramuscular injections every 8\u2005weeks without oral lead-in. Plasma and IC drug concentrations in peripheral blood mononuclear cells were measured at baseline and at every follow-up visit over 12\u2005months. Virological suppression, immunological parameters and correlations with PK data were analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, 93.6% of participants had undetectable viral load (&amp;lt;20\u2005copies\/mL). CAB and RPV plasma trough concentrations showed moderate intra-individual and high inter-individual variability, with RPV IC accumulation \u223c 5-fold higher than plasma, and CAB IC exposure about 15% of plasma levels. A transient decrease in plasma and IC concentrations was observed at month 3, without impact on virological suppression. Virological blips occurred in 15.3% of participants, with no significant association to drug concentrations. Two virological failures are reported with onset of NNRTI and INSTI major and accessory resistance mutation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>LA CAB and RPV achieve plasma exposures consistent with clinical trials, maintaining virological suppression despite pharmacokinetic variability. Intracellular accumulation, especially of RPV, may contribute to sustained virological control. These findings support the use of LA CAB\/RPV as a robust ART option in real-world clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag113","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:59:55Z","timestamp":1773838795000},"source":"Crossref","is-referenced-by-count":1,"title":["The plasma and intracellular exposure of intramuscularly administered long-acting cabotegravir and rilpivirine in people with HIV"],"prefix":"10.1093","volume":"81","author":[{"given":"Micol","family":"Ferrara","sequence":"first","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medical Sciences, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Maccario","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medical Sciences, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Barrera","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medical Sciences, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ponzetta","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medical Sciences, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Di Girolamo","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medical Sciences, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daigoro","family":"Arrue Diaz","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medical Sciences, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmaria","family":"Bo","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medical Sciences, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Carlo","family":"Orofino","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, \u2018Divisione A\u2019, Amedeo di Savoia Hospital , Turin 10149 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Maiese","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Soloperto","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5973-9948","authenticated-orcid":false,"given":"Amedeo","family":"De Nicol\u00f2","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"D\u2019Avolio","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2534-8815","authenticated-orcid":false,"given":"Andrea","family":"Calcagno","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medical Sciences, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7537-3341","authenticated-orcid":false,"given":"Stefano","family":"Bonora","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medical Sciences, University of Turin , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"2026041702463464600_dkag113-B1","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/jac\/dkae080","article-title":"Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals","volume":"79","author":"Cossu","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026041702463464600_dkag113-B2","doi-asserted-by":"publisher","first-page":"100793","DOI":"10.1016\/j.lanepe.2023.100793","article-title":"Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland","volume":"36","author":"Thoueille","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2026041702463464600_dkag113-B3","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1093\/cid\/ciad020","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection: 152-week results from ATLAS-2 M, a randomized, open-label, phase 3b, noninferiority study","volume":"76","author":"Overton","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026041702463464600_dkag113-B4","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"},{"key":"2026041702463464600_dkag113-B5","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S1473-3099(15)00152-8","article-title":"Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomized, phase 2b, dose-ranging trial","volume":"15","author":"Margolis","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2026041702463464600_dkag113-B6","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1016\/S2352-3018(20)30106-5","article-title":"Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial","volume":"7","author":"Landovitz","year":"2020","journal-title":"Lancet HIV"},{"key":"2026041702463464600_dkag113-B7","doi-asserted-by":"publisher","first-page":"e00899","DOI":"10.1128\/AAC.00899-16","article-title":"Population pharmacokinetics and pharmacogenetics analysis of rilpivirine in HIV-1-infected individuals","volume":"61","author":"Aouri","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026041702463464600_dkag113-B8","doi-asserted-by":"publisher","first-page":"e668","DOI":"10.1016\/S2352-3018(21)00184-3","article-title":"Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"2026041702463464600_dkag113-B9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/ph14010012","article-title":"Validation of a UHPLC-MS\/MS method to quantify twelve antiretroviral drugs within peripheral blood mononuclear cells from people living with HIV","volume":"14","author":"De Nicol\u00f2","year":"2020","journal-title":"Pharmaceuticals"},{"key":"2026041702463464600_dkag113-B10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jpba.2014.05.040","article-title":"UPLC\u2013MS\/MS method for quantification of the azathioprine metabolites 6-mercaptoguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells","volume":"98","author":"De Nicol\u00f2","year":"2014","journal-title":"J Pharm Biomed Anal"},{"key":"2026041702463464600_dkag113-B11","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/cid\/ciae475","article-title":"Virological history predicts non-sustained viral suppression with long-acting cabotegravir and rilpivirine therapy, independent of pharmacokinetic parameters","volume":"80","author":"Guti\u00e9rrez","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026041702463464600_dkag113-B12","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.3390\/pharmaceutics14081588","article-title":"Real-life therapeutic concentration monitoring of long-acting cabotegravir and rilpivirine: preliminary results of an ongoing prospective observational study in Switzerland","volume":"14","author":"Thoueille","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026041702463464600_dkag113-B13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/cid\/ciae016","article-title":"Virological failure after switch to long-acting cabotegravir and rilpivirine injectable therapy: an in-depth analysis","volume":"79","author":"Van Welzen","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026041702463464600_dkag113-B14","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1080\/14787210.2022.2081153","article-title":"Cabotegravir\/rilpivirine: the last FDA-approved drug to treat HIV","volume":"20","author":"Taki","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026041702463464600_dkag113-B15","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40262-021-01005-1","article-title":"Pharmacokinetics and drug\u2013drug interactions of long-acting intramuscular cabotegravir and rilpivirine","volume":"60","author":"Hodge","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2026041702463464600_dkag113-B16","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/cid\/ciad370","article-title":"Expanded multivariable models to assist patient selection for long-acting cabotegravir + rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure","volume":"77","author":"Orkin","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026041702463464600_dkag113-B17","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1093\/cid\/ciac631","article-title":"First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable human immunodeficiency virus (HIV) viremia in an urban HIV clinic","volume":"76","author":"Christopoulos","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026041702463464600_dkag113-B18","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/QAD.0000000000003446","article-title":"Single-center experience evaluating and initiating people with HIV on long-acting cabotegravir\/rilpivirine","volume":"37","author":"Hill","year":"2023","journal-title":"AIDS"},{"key":"2026041702463464600_dkag113-B19","first-page":"069","article-title":"Doravirine and rilpivirine intra cellular accumulation in the clinical setting","volume":"3","author":"Ferrara","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"2026041702463464600_dkag113-B20","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/cid\/ciae060","article-title":"Effect of obesity on the exposure of long-acting cabotegravir and rilpivirine: a modeling study","volume":"79","author":"Bettonte","year":"2024","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/5\/dkag113\/68099051\/dkag113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/5\/dkag113\/68099051\/dkag113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:46:42Z","timestamp":1776408402000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag113\/8592905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag113","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,3]]},"article-number":"dkag113"}}